Stock Screener App

無料 -

インストール

0.228

0.87% -0.002

Theriva Biologics Inc (TOVX)

概要ニュース株価時系列ディスカッション予測

Theriva Biologics Inc (TOVX) 最新ニュース

Maxim Group Maintains Theriva Biologics(TOVX.US) With Buy Rating, Maintains Target Price $1 - Moomoo

Theriva Biologics Releases Q2 2026 Financial Results - AlphaStreet

Form 8K Theriva Biologics Inc For: 11 August By Investing.com - Investing.com Nigeria

Theriva Biologics, Inc. 2026: Revenue ($3.35M), Net income ($3.22M), EPS ($0.07) — 10-Q Summary - TradingView

Theriva Biologics reports $3.2 million Q2 loss and VCN-01 dosing progress - Quiver Quantitative

Theriva Biologics reports Q2 2026 results; $11.3M cash, net loss $3.2M for quarter - TradingView

Theriva Biologics (NYSE American: TOVX) narrows Q2 loss, advances VCN-01 trial - Stock Titan

Theriva Biologics: Q2 Earnings Snapshot - marketscreener.com

BRIEF-Theriva Biologics Q2 Net Income USD -3.217 Million - TradingView

Theriva™ Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results - Yahoo Finance UK

TOVX Stock Price and Chart — AMEX:TOVX - TradingView

Theriva Biologics Inc (TOVX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Theriva doses first patient in VCN-01 pancreatic cancer trial By Investing.com - Investing.com South Africa

Theriva Biologics Doses First Patient in VIRAGE2 Phase 2a Trial to Refine VCN-01 Therapy for Metastatic Pancreatic Cancer – Minichart - Minichart

Form 8K Theriva Biologics Inc For: 6 August By Investing.com - Investing.com Nigeria

Theriva Biologics (NYSE American: TOVX) starts VIRAGE2 Phase 2a trial in PDAC - Stock Titan

Theriva’s Six-Patient Cancer Trial Is Designed to Test Repeat Virus Dosing - Stock Titan

Theriva Biologics Expands Stock Incentive and Governance Plans - TipRanks

Theriva Biologics (NYSE American: TOVX) holders back bigger stock plan, warrants - Stock Titan

Theriva Biologics, Inc. Revenue Breakdown – AMEX:TOVX - TradingView

TOVX|Theriva Biologics Inc|Price:0.222|Chg%:+0.012 - TradingKey

Theriva Biologics Inc (TOVX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Theriva Biologics Inc (TOVX) Cash Flow - TradingKey

TOVX|Theriva Biologics Inc|Price:0.214|Chg%:-0.009 - TradingKey

Theriva Biologics Inc (TOVX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Theriva Biologics Inc (TOVX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Theriva Biologics Inc (TOVX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Theriva Biologics, Inc. Revenue Breakdown – BOATS:TOVX - TradingView

Theriva Biologics Inc (TOVX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

TOVX|Theriva Biologics Inc|Price:0.223|Chg%:-0.001 - TradingKey

Theriva Biologics (TOVX) Proxy Filing Summary - Quartr

Theriva Biologics (TOVX) Slides 5% as Selling Pressure Mounts Near Key SupportMomentum Stock Picks - dars.gov.et

Theriva Biologics (TOVX) Declines 5.6% as Stock Tests Key Support LevelsAI Trade Signals - dars.gov.et

symbol__ Stock Quote Price and Forecast - CNN

Theriva Biologics (TOVX) Secures Approval for VIRAGE2 Clinical T - GuruFocus

Theriva Biologics Gets Spain Approval for Phase 2a Trial of Pancreatic Cancer Therapy - Moomoo

Theriva Biologics launches VIRAGE2 metastatic pancreatic trial - TipRanks

Theriva Biologics cleared to start VIRAGE2 trial | TOVX 8-K Filing - Stock Titan

Theriva Biologics receives approval to start VIRAGE2 cancer trial By Investing.com - Investing.com Canada

Theriva™ Biologics Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma - The Manila Times

Theriva wins Spain nod for more frequent VCN-01 dosing in pancreatic cancer trial - Stock Titan

Theriva Biologics (TOVX) Holds Steady Near Support After Modest GainOrder Block - DonanımHaber

Form DEF 14A THERIVA BIOLOGICS For: 29 June By Investing.com - Investing.com Nigeria

Theriva Biologics (NYSE American: TOVX) puts large share and warrant proposals to vote - Stock Titan

Enterprise value to EBIT forward of Theriva Biologics, Inc. – AMEX:TOVX - TradingView

Price to book forward of Theriva Biologics, Inc. – AMEX:TOVX - TradingView

Enterprise value to EBIT forward of Theriva Biologics, Inc. – FWB:SFY0 - TradingView

Enterprise value to EBITDA forward of Theriva Biologics, Inc. – FWB:SFY0 - TradingView

Enterprise value to revenue forward of Theriva Biologics, Inc. – FWB:SFY0 - TradingView

Price to sales forward of Theriva Biologics, Inc. – AMEX:TOVX - TradingView

Price to earnings forward of Theriva Biologics, Inc. – AMEX:TOVX - TradingView

Price to earnings forward of Theriva Biologics, Inc. – FWB:SFY0 - TradingView

Theriva Biologics Company Profile & Introduction - Moomoo

Theriva Biologics, Inc. Actuals & Estimates (AMEX:TOVX) - TradingView

TOVX Forecast — Price Target — Prediction for 2027 - TradingView

Theriva Biologics, Inc. Actuals & Estimates (FWB:SFY0) - TradingView

SFY0 Forecast — Price Target — Prediction for 2027 - TradingView

Theriva Biologics Inc (TOVX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Theriva Biologics (TOVX) Proxy filing Summary - Quartr

TOVX Should I Buy - Intellectia AI

Theriva Biologics (TOVX) asks shareholders to approve share, plan and warrant changes - Stock Titan

MRNA

$63.32

0.52%

RPRX

$58.60

0.07%

ROIV

$36.20

0.22%

INSM

$123.74

2.05%

ALNY

$228.65

0.67%

ONC

$347.48

2.40%

Yahooで開く | Google で開く | Finviz で開く | マーケットウォッチで開く | ロイターで開く